3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
25
Phase 1
15
Phase 1/2
4
Phase NA
2
Phase 3
2
Phase EARLY_PHASE1
1
Phase 4
1
Status
Completed
15
Unknown
6
Terminated
4
Withdrawn
1
Recruiting
1
Not yet recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Breast Neoplasms
33
Neoplasms
17
Prostatic Neoplasms
14
Lung Neoplasms
12
Carcinoma, Hepatocellular
11
Carcinoma, Non-Small-Cell Lung
10
Multiple Myeloma
9
Colorectal Neoplasms
9
Precursor Cell Lymphoblastic Leukemia-Lymphoma
6
Papillomavirus Infections
6
Pain, Postoperative
6
Neoplasm Metastasis
6
Leukemia, Myeloid, Acute
6
Stomach Neoplasms
5
Recurrence
5
Liver Neoplasms
5
Lymphoma, Non-Hodgkin
4
Kidney Neoplasms
4
Heart Failure
4
Glioma
4
Febrile Neutropenia
4
Carcinoma, Renal Cell
4
Brain Neoplasms
4
Warts
3
Uterine Cervical Neoplasms
3
Urinary Bladder Neoplasms
3
Skin Neoplasms
3
Rectal Neoplasms
3
Pituitary Neoplasms
3
Pancreatic Neoplasms
3
Interventions
nilotinib
1
bosutinib
1
asciminib
1
Imatinib Mesylate
1
Dasatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 4
×
Recruiting
×
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
×
Clear all
NCT04877522
2026-05-11
Asciminib Roll-over Study
Novartis
Phase 4
Recruiting
347 enrolled